Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
VitaSynth is a Polish biotechnology company that specializes in the advanced chemical synthesis of high-purity vitamins and pharmaceutical ingredients. The company is globally recognized for developing a proprietary, non-fermentation-based synthesis process for Vitamin K2 in the form of menaquinone-7 (MK-7). This technology allows for the production of an exceptionally pure and stable "all-trans" isomer, which is the biologically active form of the vitamin. VitaSynth operates primarily as a research and manufacturing entity, providing its specialized ingredients to the global nutraceutical and pharmaceutical markets. Their work is rooted in deep expertise in organic chemistry and process scale-up, often collaborating with international distributors to bring their products to market.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on VitaSynth.